Axsome Therapeutics (AXSM) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Axsome Therapeutics (AXSM) right now is Auvelity revenue ramp: Auvelity is the dominant driver, posting ~$153M in Q1 2026 net sales (up ~59% year over year) and accounting for most of company revenue. Revenue (Q1 2026) is ~$191M (up ~57% YoY). If that keeps playing out, the setup is favourable; the risk to it is axsome remains unprofitable, reporting a Q1 2026 net loss of roughly $64.5M (about $1.26 per share), so the equity depends on future growth rather than current earnings. No one can predict where AXSM trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Axsome Therapeutics (AXSM) higher?
1. Auvelity revenue ramp
Auvelity is the dominant driver, posting ~$153M in Q1 2026 net sales (up ~59% year over year) and accounting for most of company revenue. Continued prescriber adoption in major depressive disorder is the single biggest determinant of the growth trajectory. Management has publicly framed a multi-billion-dollar peak-sales opportunity, so the market watches quarterly script trends closely.
2. Label and indication expansion
Auvelity gained approval for agitation associated with Alzheimer's dementia, with a broader commercial launch targeted for mid-2026, opening a second large patient population. Widening the addressable market beyond MDD is central to the bull framing. Each new indication also lengthens the runway of the existing commercial infrastructure.
3. Pipeline read-outs and filings
Axsome has filed an NDA for AXS-12 in cataplexy and carries earlier assets like AXS-20 (balipodect) for schizophrenia and Tourette syndrome. Positive regulatory and trial outcomes could add new revenue lines and diversify away from single-product concentration. These catalysts also add binary, event-driven volatility.
4. Diversified commercial base
Sunosi (~$34M in Q1 2026, up ~34% year over year) and the newer Symbravo migraine product provide additional, growing revenue streams beyond Auvelity. A broader in-market portfolio can smooth reliance on any one launch. It also leverages the same neuroscience-focused sales force.
What could weigh on AXSM?
Axsome remains unprofitable, reporting a Q1 2026 net loss of roughly $64.5M (about $1.26 per share), so the equity depends on future growth rather than current earnings. Revenue is heavily concentrated in Auvelity, meaning any slowdown in that launch, payer pushback, or competitive entry would weigh heavily. Cash of about $305M at March 31, 2026 against ongoing losses raises the possibility of future capital needs or dilution. Pipeline and regulatory outcomes are binary and can move the stock sharply, and eventual patent or generic competition across CNS categories is a longer-term overhang. The valuation prices in substantial execution, leaving limited margin for disappointment.
Where AXSM trades today
A forecast starts from where the stock actually is. These are AXSM's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for AXSM as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a AXSM forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the AXSM guide and whether AXSM is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the AXSM outlook
The bottom line: what is driving Axsome Therapeutics (AXSM) is Auvelity revenue ramp, with revenue (q1 2026) at ~$191M (up ~57% YoY). If that keeps playing out the setup is favourable; the risk is axsome remains unprofitable, reporting a Q1 2026 net loss of roughly $64.5M (about $1.26 per share), so the equity depends on future growth rather than current earnings. No one can predict the price, so treat any AXSM forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around AXSM with Walnut
Use Axsome Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Axsome Therapeutics (AXSM)?
+
No one can reliably predict where AXSM will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Axsome Therapeutics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive AXSM higher?
+
The main growth drivers are Auvelity revenue ramp; Label and indication expansion; Pipeline read-outs and filings. Whether they play out is the real question, not a guaranteed path.
What are the risks to AXSM?
+
Axsome remains unprofitable, reporting a Q1 2026 net loss of roughly $64.5M (about $1.26 per share), so the equity depends on future growth rather than current earnings. Revenue is heavily concentrated in Auvelity, meaning any slowdown in that launch, payer pushback, or competitive entry would weigh heavily. Cash of about $305M at March 31, 2026 against ongoing losses raises the possibility of future capital needs or dilution. Pipeline and regulatory outcomes are binary and can move the stock sharply, and eventual patent or generic competition across CNS categories is a longer-term overhang. The valuation prices in substantial execution, leaving limited margin for disappointment.
Will AXSM stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Axsome Therapeutics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is AXSM a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the AXSM "is it a buy?" page for a framework. Walnut is not an investment adviser.
How big is Axsome and how fast is it growing?
+
As of mid-2026 AXSM had a market cap of roughly $12.4B. Q1 2026 net product revenue was about $191M, up roughly 57% year over year, led by Auvelity and supported by Sunosi and the newer Symbravo.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.